

AD-GPT: Large Language Models in Alzheimer’s Disease

Ziyu Liu¹, Lintao Tang², Zeliang Sun³, Zhengliang Liu⁴,
YanJun Lyu⁵, Wei Ruan⁴, Yangshuang Xu², Liang Shan²,
Jiyoon Shin¹, Xiaohe Chen², Dajiang Zhu⁵, Tianming Liu⁴,
Rongjie Liu^{1*}, Chao Huang^{3*}

¹Department of Statistics, University of Georgia, Athens, GA, USA.

²Department of Statistics, Florida State University, Tallahassee, FL, USA.

³Department of Epidemiology & Biostatistics, University of Georgia, Athens, GA, USA.

⁴School of Computing, University of Georgia, Athens, GA, USA.

⁵Department of Computer Science and Engineering, University of Texas at Arlington, Arlington, TX, USA.

*Corresponding author(s). E-mail(s): rjliu@uga.edu;
chaohuang@uga.edu;

Contributing authors: zl23565@uga.edu; lt20ca@fsu.edu;
zs58484@uga.edu; zl18864@uga.edu; yxl9168@mavs.uta.edu;
wei.ruan@uga.edu; yx23e@fsu.edu; ls21s@fsu.edu; js12571@uga.edu;
xchen8@fsu.edu; dajiang.zhu@uta.edu; tliu@uga.edu;

Abstract

Large language models (LLMs) have emerged as powerful tools for medical information retrieval, yet their accuracy and depth remain limited in specialized domains such as Alzheimer’s disease (AD), a growing global health challenge. To address this gap, we introduce AD-GPT, a domain-specific generative pre-trained transformer designed to enhance the retrieval and analysis of AD-related genetic and neurobiological information. AD-GPT integrates diverse biomedical data sources, including potential AD-associated genes, molecular genetic information, and key gene variants linked to brain regions. We develop a stacked LLM architecture combining Llama3 and BERT, optimized for four critical tasks in

AD research: (1) genetic information retrieval, (2) gene–brain region relationship assessment, (3) gene–AD relationship analysis, and (4) brain region–AD relationship mapping. Comparative evaluations against state-of-the-art LLMs demonstrate AD-GPT’s superior precision and reliability across these tasks, underscoring its potential as a robust and specialized AI tool for advancing AD research and biomarker discovery.

1 Main

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that profoundly impacts memory, cognition, and behavior [1]. It typically begins with subtle memory impairment and confusion, gradually advancing to severe deficits in language, spatial orientation, and executive function [2]. As the global burden of AD continues to rise, large-scale biomedical studies have emerged, generating vast datasets across diverse modalities, including neuroimaging, genomics, neurocognitive assessments, and clinical profiles [3]. These extensive datasets have facilitated the identification of key biomarkers implicated in AD onset and progression, offering critical insights into its underlying pathological mechanisms. However, efficiently integrating these findings from existing literature and databases still remains a significant challenge, which underscores the immense value offered by large-scale studies in driving the advancement of diagnostic and therapeutic strategies for AD patients.

Information retrieval (IR) is an important tool that focuses on the identification and extraction of relevant information from vast datasets or document collections [4]. In the context of AD research, IR plays a pivotal role by enabling the efficient access to critical data, thereby supporting a wide array of research applications. For instance, IR facilitates the retrieval of biomarker data, such as beta-amyloid plaque levels or tau protein concentrations, which provide valuable insights into disease mechanisms and enhance early diagnostic capabilities [5]. Additionally, IR is instrumental in accessing medical imaging data from repositories, allowing researchers to track and analyze patterns of brain atrophy and functional changes over time [6]. Furthermore, IR aids in identifying genetic studies [7], which could include those investigating APOE polymorphisms, which are strongly linked to AD risk. Therefore, IR is essential for navigating the growing body of AD research, ensuring that crucial data is accessible for advancing our understanding and treatment of AD.

Large Language Models (LLMs) are advanced tools in natural language processing (NLP) that have demonstrated remarkable capabilities across various domains. These models, such as the GPT (Generative Pre-trained Transformer) series, including ChatGPT and Llama, are designed to understand and generate human-like text, which makes them particularly effective for addressing challenges in IR [8]. In particular, LLM-based IR can streamline the process of retrieving complex biomedical databases, such as clinical records that focus on the relationships between various phenotypes and genotypes, making it an invaluable tool for AD researchers [9].

Although LLMs have demonstrated broad applicability in IR within the medical domain [10–13], they also exhibit several critical limitations. One of the most significant concerns is their propensity for hallucination, a phenomenon in which models generate responses that appear confident yet are factually incorrect or nonsensical [14]. This issue becomes particularly pronounced in tasks requiring domain-specific expertise, such as medical and legal inquiries, where LLMs frequently produce fabricated information presented with unwarranted certainty [15]. Beyond hallucination, LLMs often fall short in providing depth and comprehensiveness, particularly in specialized contexts. While models like ChatGPT can generate largely accurate responses, they are frequently criticized for their lack of nuanced understanding. For instance, in the field of epilepsy, LLM-generated content is often superficial, failing to capture the intricacies of the condition [16]. Similarly, in genetics, empirical evaluations suggest that ChatGPT’s performance is comparable to that of human respondents, offering no clear advantage in accuracy or insight [17]. These limitations largely stem from the models’ constrained exposure to medical-domain knowledge and their inherent difficulty in navigating the complexities of clinical reasoning.

To address these limitations, researchers have sought to enhance LLMs by fine-tuning them with domain-specific corpora. Notable efforts, such as Meditron [11], HuaTuo [12], and ChatDoctor [13], exemplify attempts to embed biomedical expertise within LLM architectures, improving their applicability in clinical and research settings. Meanwhile, given the expansive body of AD research spanning genomics, proteomics, and other disciplines, there exists a wealth of literature and publicly available datasets. Despite these advances, to date, only a single research group has proposed an LLM-driven IR system tailored specifically for AD [10]. However, this model primarily functions as a tool for retrieving news updates and extracting spatio-temporal data, rather than leveraging rigorously curated datasets or generating domain-informed insights. This reliance on unstructured, non-validated sources raises concerns regarding information reliability, data validity, and the model’s constrained analytical depth. Therefore, bridging this gap requires the development of specialized LLM frameworks capable of harmonizing structured biomedical databases with unstructured textual knowledge, ultimately unlocking their full potential for advancing AD research.

In this paper, we introduced AD-GPT, a fine-tuned stacked model designed to systematically integrate domain-specific LLMs to enhance AD research (Fig. 1). Our approach establishes a structured workflow that begins with the acquisition and curation of high-quality genetic and transcriptomic datasets from reputable public sources, such as the Online Mendelian Inheritance in Man (OMIM) [18] and the Genotype-Tissue Expression (GTEx) Project [19]. These data were meticulously processed to construct a specialized textual corpus for supervised fine-tuning, enabling the model to capture the intricate relationships between genetic factors, brain regions, and AD pathology. Beginning with comprehensive data acquisition from reputable public genetic data sources, we structured genetic, transcriptomics, and AD-related data to build the textual corpus for supervised fine-tuning. Four distinct corpora were constructed, each tailored specifically for one of four defined tasks: genetic information retrieval (Task 1), gene-brain region relationship assessment (Task 2), gene-AD relationship analysis (Task 3), and brain region-AD relationship mapping (Task 4). To




Fig. 1: Overview of the AD-GPT workflow. AD-GPT integrates multimodal data from publicly available databases, including OMIM and the GTEx Project, to systematically extract AD-related information. This information is curated into four specialized textual corpora, each designed to support distinct research tasks. The system builds upon pre-trained Llama and BERT models, further fine-tuned to enhance performance in domain-specific applications. Model efficacy is benchmarked against state-of-the-art language models using diverse evaluation metrics. To facilitate accessibility and usability, the entire framework is encapsulated within a Docker container and equipped with an interactive GUI, enabling seamless deployment for AD research.

effectively handle this multi-task problem, we implemented a stacked model where a BERT classifier deterministically classifies user queries and selects the appropriate task model to generate responses. BERT was utilized for Task 2 due to its effectiveness in classification scenarios, while the Llama model was employed for the remaining tasks, which required more nuanced generative reasoning capabilities. This structured approach ensures precise, contextually relevant responses to various AD-related inquiries. Furthermore, to rigorously assess AD-GPT’s capabilities, we conducted

extensive comparative evaluations against state-of-the-art LLMs across the four AD-related tasks. The results highlight AD-GPT’s superior performance, underscoring its potential as a reliable and precise tool for advancing AD research.

To ensure seamless deployment and user-friendly interaction, AD-GPT is encapsulated within a Docker container, integrating all model components and the FastAPI backend into a self-contained environment. This streamlined architecture minimizes configuration requirements, allowing for effortless system initialization. The platform features an HTML-based graphical user interface (GUI), providing an intuitive and accessible framework for researchers and clinicians to engage with the model. Moreover, the modular design of AD-GPT facilitates scalability and iterative enhancements, enabling seamless integration of future updates and refinements while maintaining system stability and efficiency.

2 Results

To evaluate the performance of AD-GPT, we benchmarked it against several state-of-the-art LLMs, including ChatGPT o1 [20], Claude series including Claude3.5-Haiku and Claude3.7-Sonnet [21], DeepSeek-R1-Distill-Llama-8B [22], Gemini1.5-Flash [23], Llama series including Llama2, Llama3.1, and Llama3.2 [24], Qwen2.5 [25], and Grok3 [26]. These models vary in scale and optimization strategies, providing a diverse benchmark for evaluating biomedical knowledge retrieval and reasoning capabilities (Method Section 4.3).

For Tasks 1 and 2, which involved structured queries and binary classification, we utilized standard evaluation metrics, including accuracy, precision, recall, and F1-score. The datasets for these tasks comprised 2,160 and 10,140 instruction-output pairs, respectively, covering diverse combinations of genes, brain regions, and query types (Method Section 4.1 and 4.2). A randomly selected 10% subset of each dataset was designated as the test set for computing performance metrics.

In contrast, Tasks 3 and 4 required complex text generation and advanced reasoning capabilities, necessitating qualitative evaluation via expert assessment. We enlisted multiple domain experts to systematically evaluate the responses generated by AD-GPT and comparator LLMs. The assessment criteria were based on two key metrics: relevance, which measured the contextual appropriateness of responses, and precision, which quantified the factual correctness of generated content relative to established references. Each response was rated on a 0–5 scale, with higher scores indicating superior performance. To ensure robustness and fairness in evaluation, we generated 20 novel queries for each of Tasks 3 and 4, all of which were unseen during model fine-tuning. Responses from AD-GPT and benchmark models were independently rated by three domain experts. The final performance scores were determined by averaging the ratings across experts, providing an unbiased and consistent assessment of model capabilities.

In Task 1, our base AD-GPT outperformed all competing models across all evaluated metrics (Fig. 2 (a) and Supplementary Table 1). Notably, AD-GPT achieved an accuracy of 90.84%, substantially surpassing Qwen2.5 (17.14%), Llama2 (59.59%), Llama3.1-70B (70.52%) and Claude3.5-Haiku (74.28%), and demonstrating a clear

advantage over ChatGPT o1 (85.33%). While ChatGPT o1 performed well with structured inputs, its accuracy declined for shorter or ambiguous queries, whereas Llama3.2-1B struggled markedly with less well-defined input structures. These results highlight the critical role of domain-specific optimization, as our fine-tuned AD-GPT consistently delivered superior accuracy and reliability, establishing it as a powerful tool for gene attribute-related question answering.




Fig. 2: Performance comparison of different language models across four tasks. (a) Accuracy in Task 1 for answering gene-attribute-related questions. (b) Precision, recall, and F1 score in Task 2 for identifying gene–brain region relationships. (c) Average precision and relevance scores (0–5) in Task 3 rated by experts. (d) Average precision and relevance scores (0–5) in Task 4 rated by experts.

The performance results for Task 2 highlight the exceptional capability of our BERT-based AD-GPT model in evaluating gene–brain region relationships (Fig. 2 (b) and Supplementary Table 1). Notably, our model achieved a perfect score of 100% across accuracy, precision, recall, and F1-score, demonstrating its robustness in identifying significant variants that influence gene expression or splicing regulation within specific brain regions. In contrast, alternative models, including DeepSeek Distilled Llama3.1-8B, Llama3.2-1B, and Llama3.1-70B, exhibit substantially lower accuracies (approximately 66–70%). While Qwen2.5-7B achieves a comparable accuracy of 99.83%, its reduced recall and F1-score suggest inconsistencies in performance. These findings underscore the effectiveness of our domain-specific fine-tuning in delivering

precise and reliable analyses, establishing AD-GPT as a powerful tool for evaluating gene–brain region relationships.

For Tasks 3 and 4, we benchmarked our fine-tuned model against state-of-the-art LLMs, including Llama3.1-8B, Llama3.2-3B, Claude3.5-Haiku, Claude3.7-Sonnet, Gemini1.5-Flash, Grok3, DeepSeek-R1-Distill-Llama-8B, and ChatGPT o1. AD-GPT consistently outperformed all competing models across both tasks (Fig. 2 (c)-(d) and Supplementary Table 2). In Task 3, AD-GPT achieved the highest scores, with a precision of 4.70 and a relevance of 4.92, whereas alternative models, including DeepSeek-R1-Distill-Llama-8B, ChatGPT o1, and Gemini1.5-Flash, exhibited lower precision. Similarly, in Task 4, AD-GPT maintained its lead, scoring 4.60 in precision and 4.90 in relevance, surpassing Llama models, DeepSeek-R1-Distill-Llama-8B, Gemini1.5-Flash, ChatGPT o1, and Claude3.5-Haiku. These findings highlight a critical limitation of general-purpose models: while some exhibit reasonable relevance, they frequently struggle with factual accuracy and reliable citation. The superior performance of AD-GPT underscores the efficacy of domain-specific fine-tuning in enhancing both precision and contextual relevance in specialized applications.

To comprehensively evaluate the effectiveness of fine-tuning, we compared the performance of the fine-tuned model AD-GPT against its pre-trained counterpart, Llama3.1-8B, on Tasks 3 and 4. AD-GPT was fine-tuned using Quantized Low-Rank Adaptation (QLoRA), specifically targeting the grouped-query attention (GQA) and feed-forward layers. LoRA introduced about 134 million new weights, which is 1.675% of the total number of weights in Llama3.1-8B. This fine-tuning strategy substantially improved complex text generation and advanced reasoning, where expert evaluations revealed a marked increase in both relevance and precision, i.e., 20.6% and 2.8% in Task 3 while 27% and 12.4% in Task 4 (Supplementary Table 2). Furthermore, as shown in Fig. 3, LoRA fine-tuning dramatically shifted the distribution of precision scores for Task 3 ($t(19)=4.64$, $P < 0.001$, Cohen’s $d=1.45$, 95% CI 0.58-1.43; two sided). In Task 4, AD-GPT further demonstrated superior performance in both precision ($t(19)=5.20$, $P < 0.001$, Cohen’s $d=1.84$, 95% CI 0.87-1.75; two sided) and relevance ($t(19)=6.32$, $P < 0.001$, Cohen’s $d=2.13$, 95% CI 0.43-0.78; two sided) ratings, underscoring the effectiveness of QLoRA fine-tuning in enhancing model capability for AD-related biomedical tasks.

To further evaluate the reliability of AD-GPT and competing LLMs, we randomly selected one representative question from each task and systematically analyzed the responses generated by AD-GPT and its counterparts (Fig. 4). AD-GPT consistently provided accurate and contextually appropriate answers across all tasks. In contrast, we identified notable deficiencies in competing LLMs, which varied depending on the nature of the task. In Tasks 1 and 2, several models, including ChatGPT o1, Grok3, Gemini1.5-Flash, and DeepSeek-R1-Distill-Llama-8, either failed to generate responses or produced inaccurate answers, likely due to their limited exposure to domain-specific knowledge. In Tasks 3 and 4, other models, such as Llama3.1-8B and Claude3.7-Sonnet, frequently generated ambiguous statements or fabricated references to support their conclusions, undermining their credibility. These findings highlight the importance of domain adaptation in LLM development and underscore the advantages of AD-GPT in handling specialized inquiries with greater precision and reliability.




Fig. 3: Performance improvements of AD-GPT following QLoRA fine-tuning on Tasks 3 and 4. The QLoRA fine-tuning process substantially shifted the distributions of precision and relevance scores for both tasks. Two-sided paired t -tests were conducted to evaluate the statistical significance of these metric improvements. Cohen's d and 95% confidence intervals are reported to quantify the effect sizes.

3 Discussion

Model and metric selection for performance comparison have already been carried out. In Task 1, we restricted our comparison to LLMs with at least some genetic knowledge. Smaller models, such as Llama3.1-7B, Gemini1.5-Flash, and DeepSeek-R1-Distilled-Llama-3-7B, struggled with these queries, frequently producing indecisive or incorrect responses. In Task 2, given that our model is based on BERT and relatively




Fig. 4: Representative questions randomly selected from Tasks 1-4 and the responses generated by AD-GPT and its counterparts. AD-GPT consistently demonstrates more accurate, specific, and evidence-backed answers across a range of genomic and disease-association queries.

lightweight, we conducted a horizontal comparison against similarly compact architectures, including Llama3.2-1B and Llama3.1-8 B. As Task 2 is formulated as a binary classification problem, we employed accuracy, precision, recall, and F1 score as evaluation metrics to ensure a rigorous and comprehensive assessment. For all tasks except Task 2, we selected ChatGPT o1 as an alternative baseline but excluded models such as GPT-3 and GPT-4 for several reasons. First, ChatGPT o1 represents the most recent publicly accessible model from OpenAI, providing a more equitable benchmark against our AD-GPT, which is similarly designed for practical deployment without proprietary access constraints. In contrast, models like GPT-4 operate behind closed APIs, limiting transparency, reproducibility, and direct evaluation. Furthermore, state-of-the-art LLMs such as GPT-4 frequently integrate online retrieval mechanisms to augment responses, whereas our model relies solely on internalized domain knowledge to ensure consistency and reliability in offline environments. The inclusion of retrieval-augmented models would introduce external variability, complicating direct comparisons. Finally, earlier versions such as GPT-3 exhibit insufficient specialization in genetic and biomedical domains, rendering them less relevant as comparators for our fine-tuned model.

Based on our model, AD-GPT provided more decisive responses and produced more accurate references. Our comparative analysis revealed that while state-of-the-art

large language models (LLMs), such as ChatGPT-01, Claude 3.5-Haiku, and Gemini 1.5-Flash, demonstrated remarkable versatility across diverse tasks, they exhibited notable limitations in domain-specific expertise. These models, despite their extensive parameter sizes, relied heavily on web searches and external data sources to enhance reasoning accuracy and reference reliability. This dependence on online access introduced inconsistencies, particularly when handling specialized knowledge. We observed that although the responses generated by these LLMs appeared logically structured and contextually appropriate, they often lacked decisiveness and contained ambiguities. More critically, when encountering gaps in knowledge, these models frequently produced fabricated references, i.e., citations that were either nonexistent or inaccurately attributed. This phenomenon led to the dissemination of misleading information, raising concerns about their reliability in research and decision-making contexts (Fig. 4). In contrast, AD-GPT provided precise and well-reasoned responses derived exclusively from its curated domain-specific database. Unlike conventional LLMs, our model did not generate fictitious references, ensuring that all cited information remained verifiable and directly traceable. This fundamental advantage positioned AD-GPT as a more dependable tool for specialized knowledge retrieval, particularly in high-stakes applications where accuracy and authoritative sourcing were paramount.

We have achieved easy deployment and data transparency for AD-GPT. In contrast to large-scale LLMs, such as the ChatGPT series, our AD-GPT operated as a fully self-contained system with a compact architecture. This design facilitated secure, on-premise deployment, faster inference times, and lower latency, making it feasible for real-time applications in clinical and research settings. Furthermore, the knowledge base of our AD-GPT was constructed from a rigorously curated dataset specifically tailored to AD. Unlike models that aggregated information from broad-spectrum training corpora or relied on real-time web searches, our system ensured that all embedded knowledge was sourced from validated, authoritative references. This database-driven approach not only enhanced reliability but also enabled explicit citation of sources, a crucial feature for clinical decision support and research applications. By providing transparent, evidence-backed responses, our model aligned with the stringent requirements of medical and scientific fields, offering a trustworthy tool for domain experts.

Our future efforts will focus on several key enhancements to improve the adaptability, precision, and scalability of our AD-GPT. First, we plan to incorporate Retrieval-Augmented Generation (RAG) [27] to address the limitations of our current fixed-database approach. While our model effectively answers domain-specific questions based on a predefined dataset, its knowledge remains constrained by the static nature of its training corpus. As research in AD evolves, maintaining up-to-date insights becomes increasingly critical. By integrating RAG, we aim to dynamically retrieve relevant information from external sources, such as recent publications, NCBI articles, and continuously updated medical databases. This enhancement will allow our model to generate more informed and contextually relevant responses, balancing domain-specific expertise with real-time knowledge integration. Furthermore, we intend to implement Chain-of-Thought (CoT) prompting [28] to improve logical coherence and reasoning depth in our responses. By enabling the model to generate

intermediate reasoning steps, CoT enhances interpretability and ensures a structured decision-making process. The combination of RAG and CoT will not only refine response quality but also mitigate hallucinations, strengthening reliability in medical and research applications. Second, inspired by DeepSeek R1 [29], we plan to integrate Mixture-of-Experts (MoE) and reinforcement learning (RL) to further enhance response precision and adaptability. While our current BERT classifier routes questions to separate models, MoE presents a transformative approach to multi-task learning by dynamically assigning queries to the most relevant subset of expert networks. This selective activation reduces computational and storage overhead while improving contextual awareness, facilitating nuanced knowledge transfer across tasks. Unlike maintaining full models for each task, MoE employs a shared base network with lightweight expert modules, enabling a more efficient and scalable framework for complex, multi-dimensional queries. Additionally, we will incorporate Guided Reinforcement with Preference Optimization (GRPO) to refine our model’s decision-making capabilities. By leveraging continuous feedback mechanisms, RL will enhance adaptive learning, allowing our system to iteratively improve based on user interactions and expert evaluations. The synergy between MoE and RL will optimize resource allocation while maintaining high-performance standards in specialized medical reasoning tasks.

4 Methods

4.1 Data and data collection

Genetic datasets have expanded significantly in both scale and diversity, providing a robust foundation for advancing research in AD. Our study leveraged a core set of 144 experimentally validated seed genes identified in [30], each associated with AD pathogenesis (Supplementary Data). This initial gene set served as a fundamental reference point for subsequent analyses and validation. While these 144 genes provided a starting framework, additional candidate genes could be integrated in future investigations to enhance the breadth and robustness of our findings.

Building on this foundation, we systematically curated and harmonized data from multiple high-quality sources, including the GTEx project and OMIM database (Fig. 5). The GTEx project provides extensive gene expression profiles across more than 30 non-diseased human tissue types collected from hundreds of donors. This resource enables the systematic exploration of associations between genetic variants identified in genome-wide association studies (GWAS) and disease phenotypes, offering critical insights into gene regulation mechanisms in AD. OMIM is a comprehensive and authoritative resource on human genes and genetic disorders. It contains detailed records on over 16,000 genes, including their functions, associated variants, molecular mechanisms, inheritance patterns, and links to relevant literature. This integrative approach ensured a comprehensive dataset, facilitating deeper insights into the genetic underpinnings of AD and enabling more precise downstream analyses.

From the GTEx database, we extracted cis-quantitative trait loci (cis-QTL) data, including both expression quantitative trait loci (eQTL) and splicing quantitative trait loci (sQTL), for the 144 AD seed genes using FastQTL [31], following the

analysis pipeline in GTExPortal [19]. These data were obtained from a single tissue type encompassing 13 distinct brain regions, including the frontal cortex, amygdala, anterior cingulate cortex, caudate (basal ganglia), cerebellar hemisphere, cerebellum, nucleus accumbens (basal ganglia), putamen (basal ganglia), cervical spinal cord, cortex, hypothalamus, hippocampus, and substantia nigra. Notably, gene-variant pairs often exhibit significant effects in one brain region but not in others, reflecting regional specificity in eQTL and sQTL distributions. These variations facilitate fine-mapping of potential causal variants and their corresponding neurological disease associations [32], providing a framework for identifying region-specific therapeutic targets for AD. Additionally, we extracted fundamental gene-level annotations, including chromosome location, start and end coordinates, and strand orientation, to support the genetic information retrieval. To further investigate the relationship between genotypes and AD, we further extracted the “Molecular Genetic” section from the OMIM entry of each gene (Supplementary Table 3), which provided a textual description about how genetic variants contribute to AD pathophysiology and established a robust basis for exploring genotype-phenotype relationships.

In summary, we curated a dataset of 144 AD-associated seed genes and integrated multi-omic regulatory information (Fig. 5). cis-eQTL, cis-sQTL, and basic gene information were obtained from the GTEx project, focusing on regional variations in gene expression and alternative splicing across 13 anatomically distinct human brain regions. This allowed us to construct gene-brain region associations and assess differential genetic functions within diverse neurological contexts. Additionally, we incorporated phenotypic and molecular data from the OMIM database to evaluate the functional consequences of these genes. By integrating these datasets, we established a comprehensive framework for elucidating the regulatory mechanisms underlying AD pathology and identifying potential therapeutic targets.

4.2 Corpora construction

To leverage the intrinsic relationships within multiple datasets, we constructed different corpora designed for multi-task, multi-level genomics fine-tuning. The corpora consists of four distinct training datasets, each corresponding to a specific task that encapsulates different aspects of genomics knowledge and context. Each corpus follows a standardized format aligning with instruction-based fine-tuning protocols for Llama models. Specifically, the corpora are structured with three key components: a system prompt, an input query, and a corresponding response. The system prompt is formulated as: “*You are a bioinformatics expert. Based on the following instruction, provide an accurate and professional response.*”. The input and response components vary across tasks to ensure adaptability and contextual relevance.

For Task 1, AD-GPT is designed to provide precise genetic information by structuring gene-related data into a text-based format suitable for supervised fine-tuning. The dataset is constructed using gene symbols and their corresponding chromosomal locations, including start and end positions, derived from the GTEx database. To enhance the model’s adaptability, these data points are presented in multiple textual formats. A representative structured input query is: “*what is the start position*




Fig. 5: Integration of genetic data from GTEx and OMIM. GTEx provides gene location and QTL data, while OMIM offers gene descriptions and disease associations for AD research.

of $\{gene\ symbol\}$?”). This formulation ensures that the model learns to retrieve and deliver accurate genomic coordinates in response to diverse query structures.

For Task 2, AD-GPT is designed to evaluate the relationship between specific genes and brain regions, with a particular emphasis on identifying significant genetic variations. To construct the corresponding training corpus, we compiled eQTL and sQTL data for seed genes across multiple brain regions, as curated from the GTEx portal. Gene-variant pairs were selected based on statistical significance, using q-values as the primary metric. A gene was considered associated with a brain region if it harbored one or more significant variants affecting expression or splicing functions in that region. This criterion enabled the establishment of robust gene–brain region links based on functional genomic evidence. The model was trained to generate binary responses to queries, ensuring precise and interpretable outputs. For instance, a representative query is: “Does the gene $\{gene\ symbol\}$ contain variants in the $\{brain\ region\}$ that significantly influence splicing regulation?”. This structured approach ensures

the model delivers concise, evidence-based insights, facilitating efficient and reliable interpretation of gene–brain region interactions.

For Task 3, AD-GPT is designed to investigate the associations between specific genes and AD using molecular genetics information sourced from the OMIM database. Given that OMIM entries often contain extensive genetic details, not all of which are directly relevant to AD, we implemented a systematic curation process to extract meaningful relationships. To refine the corpus, we manually identified and extracted the key reasoning components from the molecular genetics summaries, focusing on the most critical information that demonstrates gene-AD associations. This curated reasoning, along with the extracted dataset, was used as training material for the language model, enabling it to distinguish relevant genetic insights from broader molecular descriptions. A typical query could be “*Determine if {gene symbol} has a potential role in Alzheimer’s disease based on the molecular genetics summary.*”, and if the gene is related to AD, the answer will be “*Yes, there is a potential relation based on the {reasoning}.*” During training, the model was optimized to generate structured responses comprising two essential components: (1) a definitive classification indicating whether a gene-AD relationship is supported and (2) a rationale explicitly outlining the molecular evidence that underpins this classification. By incorporating explicit reasoning into the training process, the model not only ensures evidence-based outputs but also enhances its capacity for inference in complex biomedical contexts.

In Task 4, AD-GPT is designed to model the tripartite relationships among genes, AD, and brain regions. Building upon the preceding datasets, this corpus employed a CoT prompting approach, which facilitates step-by-step reasoning to enhance performance on complex inferential tasks [28]. To illustrate, in response to the query, “*Is the {brain region} related to AD with regard to gene {gene symbol}?*”, the reasoning process was explicitly structured into three sequential steps: (1) evaluating the association between the specified gene and AD, (2) assessing the relationship between the brain region and the gene, and (3) if both relationships were established, concluding that the brain region is related to AD with respect to the given gene. This structured reasoning process was embedded within the corpus, providing explicit guidance during training and improving the ability of AD-GPT in handling complex relational queries.

Representative examples of the four tasks are provided in Supplementary Tables 4–7, where each table illustrates a single example format per task. To enhance the model’s generalization capability, we incorporated diverse phrasings of the same query type within each corpus. For instance, in the task of determining a gene’s chromosomal location, training examples included variations such as “*What is the chromosome location of gene {gene symbol}?*” and “*On which chromosome is {gene symbol} located?*”. This approach ensures robustness by enabling the model to recognize and accurately respond to different formulations of the same question.

4.3 Competing LLMs for performance comparison

In this section, we summarize the key characteristics of competing LLMs that were used for performance comparison with AD-GPT.

ChatGPT o1 [20], developed by OpenAI, represents a significant advancement in artificial intelligence reasoning capabilities. The model demonstrates exceptional

performance across diverse domains, including competitive programming, advanced mathematics, and PhD-level scientific problem-solving. Notably, it exceeds human accuracy on standardized benchmarks in physics, biology, and chemistry, highlighting its potential for complex analytical tasks in biomedical research.

Claude3.5-Haiku [21] is a language model developed by Anthropic, optimized for efficiency and cost-effectiveness while maintaining high performance across multiple skill sets. Despite its compact architecture, Claude3.5-Haiku demonstrates superior capabilities on various intelligence benchmarks, surpassing even Claude 3 Opus, the largest model of the previous generation, in key performance metrics. In February 2025, Anthropic introduced Claude3.7-Sonnet, the first hybrid reasoning model, which integrates enhanced contextual understanding, improved processing speed, and advanced problem-solving capabilities. This model represents a significant advancement in AI-driven analysis and decision-making, making it particularly well-suited for biomedical applications requiring nuanced interpretation of complex datasets.

Llama3.1-8B [24] is an open-source language model with 8 billion parameters, designed to enhance reasoning, computational efficiency, and comprehension of complex biomedical tasks. It features an extended context window and improved multilingual capabilities, making it well-suited for applications such as content generation, coding assistance, and biomedical text interpretation. Llama3.2 was derived from Llama3.1 through a combination of structured pruning and knowledge distillation. Specifically, the 1B and 3B parameter models were obtained by systematically pruning Llama3.1-8B, reducing model complexity while preserving the original network's performance. This optimization process aimed to enhance computational efficiency without compromising the model's ability to process and generate high-quality biomedical text.

DeepSeek-R1-Distill-Llama-8B [22] is an open-source model developed by DeepSeek AI, derived from Llama3.1-8B through a distillation process. This distilled version maintains the high-performance capabilities of the original model while significantly improving computational efficiency. Benchmark evaluations have shown that DeepSeek-R1-Distill-Llama-8B achieves outstanding accuracy across a range of biomedical and general-domain tasks.

Gemini1.5 [23] is a model developed by Google DeepMind, which demonstrates near-perfect recall in long-context retrieval across multiple modalities. Gemini1.5 sets a new state-of-the-art performance in tasks such as long-document question answering (QA), long-video QA, and long-context automatic speech recognition (ASR). Additionally, we utilized Gemini1.5-Flash, a lightweight variant of the model, designed for enhanced efficiency while minimizing regression in performance quality.

Qwen2.5-7B [25] is a base model within the Qwen2.5 series of large language models, comprising 7.61 billion parameters. It utilizes a transformer architecture that incorporates advanced techniques such as Rotary Position Embedding (RoPE), SwiGLU activation, RMSNorm, and Attention QKV bias. The model supports a context window of up to 131,072 tokens, enabling it to process long-range dependencies effectively.

Grok3 [26], developed by xAI, is a state-of-the-art artificial intelligence model trained on the Colossus super-cluster, utilizing 10 times the computational power




Fig. 6: AD-GPT architecture overview. The AD-GPT model employs a hybrid architecture that integrates both BERT-based and Llama3-based models to address AD-related IR tasks.

of previous leading models. This significant computational scaling enables Grok3 to achieve substantial improvements in tasks requiring reasoning, mathematics, coding, and instruction-following, facilitated by large-scale reinforcement learning.

4.4 Model architecture

AD-GPT utilizes a classification-driven architecture to efficiently direct user queries to the most suitable expert model, as illustrated in Fig. 6. At the core of this design is a classification model, BERT, which first identifies the category of the user’s query and subsequently routes it to the relevant expert model. This approach, inspired by the MoE paradigm, ensures that each query is processed by the model best equipped to handle it, thereby improving both accuracy and computational efficiency.

AD-GPT is comprised of the BERT model dedicated to Task 2 and the Llama3.1-8B model used for Tasks 1, 3, and 4. The BERT-based component is utilized for token-level classification tasks and incorporates token, segment, and position embeddings. Its encoder consists of 12 transformer layers featuring multi-head attention and feedforward networks, followed by normalization layers before task-specific classification heads. Fine-tuning is performed using adapter layers, enabling efficient

transfer learning while preserving the pre-trained backbone. For reasoning-intensive tasks, the Llama3.1-8B model uses a decoder-only transformer architecture. Unlike BERT’s absolute positional embeddings, the Llama3.1-8B model utilizes rotary position embeddings, which encode relative positional information within the self-attention mechanism, improving the model’s ability to handle long-range dependencies.

4.5 Fine tuning parameters

QLoRA is an advanced fine-tuning technique designed to optimize LLMs with minimal computational and memory overhead. By utilizing 4-bit quantization, QLoRA significantly reduces the memory requirements of LLMs, enabling fine-tuning on resource-constrained hardware without compromising performance. QLoRA was applied to fine-tune Llama3.1-8B models for Tasks 1, 3, and 4. Specifically, we fine-tuned the weights of the grouped-query attention (GQA) layer and the feedforward layer. For this process, we used a low-rank adaptation dimension ($r = 64$), a scaling factor ($lora_{\alpha} = 16$), and a dropout rate ($dropout = 0.1$) to balance computational efficiency with model generalization. This configuration allowed us to adapt the Llama3.1-8B models effectively to domain-specific tasks while leveraging QLoRA’s cost-effective and scalable framework to achieve high-quality results. For Task 2, we fine-tuned the adapter layers within the feedforward and classification layers of a BERT-based model. This approach enabled task-specific adaptation while keeping the transformer backbone frozen, thereby preserving the model’s pre-trained linguistic knowledge while adapting it efficiently to biomedical tasks.

4.6 Tokenization and embedding

For both the Llama3.1-8B and BERT-based models, we retained the original tokenizers and embedding layers from the pre-trained versions, without introducing additional special tokens. While gene names and brain regions represent domain-specific terminology, we chose to preserve the pre-existing vocabulary and subword tokenization, thereby leveraging the models’ inherent linguistic and contextual knowledge.

The Llama3.1-8B model maintained its original embedding layer configuration of (128, 256, 4096), ensuring efficient representation learning without introducing additional computational overhead. Similarly, the BERT-based model retained its embedding layer structure of (30,522, 768), maintaining full compatibility with its pre-trained architecture.

Despite initial concerns that subword tokenization might limit domain-specific understanding, our fine-tuning experiments demonstrated that both models effectively captured complex gene-disease relationships, biological entity interactions, and mediation effects. This outcome was achieved without the need for vocabulary expansion. By preserving the original tokenizer and embedding layers, we optimized computational efficiency while ensuring strong performance on specialized biomedical tasks.

References

- [1] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Ch etelat, G., Teunissen, C.E., Cummings, J., Flier, W.M.: Alzheimer’s disease. *The Lancet* **397**(10284), 1577–1590 (2021)
- [2] Weiner, M.F., Neubecker, K.E., Bret, M.E., Hynan, L.S., *et al.*: Language in alzheimer’s disease. *Journal of Clinical Psychiatry* **69**(8), 1223–1227 (2008)
- [3] Gao, F., Dai, L., Wang, Q., Shi, J., Shen, Y., Consortium, N.I.C.: Chinese ADNI study: Characteristic AD biomarkers precisely predicts Alzheimer’s dementia: China aging and neurodegenerative initiative (CANDI) study. *Alzheimer’s & Dementia* **19**, 074714 (2023)
- [4] Dash, S., Pani, S.K., Balamurugan, S., Abraham, A.: Biomedical data mining for information retrieval: Methodologies, techniques, and applications (2021)
- [5] Rowan, M.: Information-selectivity of beta-amyloid pathology in an associative memory model. *Frontiers in Computational Neuroscience* **6**, 2 (2012)
- [6] Trojchanec, K., Kitanovski, I., Dimitrovski, I., Loshkovska, S.: Longitudinal brain MRI retrieval for alzheimer’s disease using different temporal information. *IEEE Access* **6**, 9703–9712 (2017)
- [7] Shatkay, H., Edwards, S., Boguski, M.: Information retrieval meets gene analysis. *IEEE Intelligent Systems* **17**(2), 45–53 (2002)
- [8] Lu, L.-C., Chen, S.-J., Pai, T.-M., Yu, C.-H., Lee, H.-y., Sun, S.-H.: LLM discussion: Enhancing the creativity of large language models via discussion framework and role-play. *arXiv preprint arXiv:2405.06373* (2024)
- [9] Dai, S., Xu, C., Xu, S., Pang, L., Dong, Z., Xu, J.: Bias and unfairness in information retrieval systems: New challenges in the LLM era. In: *Proceedings of the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining*, pp. 6437–6447 (2024)
- [10] Dai, H., Li, Y., Liu, Z., Zhao, L., Wu, Z., Song, S., Shen, Y., Zhu, D., Li, X., Li, S., *et al.*: AD-autoGPT: An autonomous GPT for Alzheimer’s disease infodemiology. *arXiv preprint arXiv:2306.10095* (2023)
- [11] Chen, Z., Cano, A.H., Romanou, A., Bonnet, A., Matoba, K., Salvi, F., Pagliardini, M., Fan, S., K opf, A., Mohtashami, A., *et al.*: Meditron-70b: Scaling medical pretraining for large language models. *arXiv preprint arXiv:2311.16079* (2023)
- [12] Wang, H., Liu, C., Xi, N., Qiang, Z., Zhao, S., Qin, B., Liu, T.: Huatuo: Tuning Llama model with Chinese medical knowledge. *arXiv preprint arXiv:2304.06975* (2023)

- [13] Li, Y., Li, Z., Zhang, K., Dan, R., Jiang, S., Zhang, Y.: Chatdoctor: A medical chat model fine-tuned on a large language model meta-AI (Llama) using medical domain knowledge. *Cureus* **15**(6) (2023)
- [14] Ji, Z., Lee, N., Frieske, R., Yu, T., Su, D., Xu, Y., Ishii, E., Bang, Y.J., Madotto, A., Fung, P.: Survey of hallucination in natural language generation. *ACM Computing Surveys* **55**(12), 1–38 (2023)
- [15] Pugliese, N., Wong, V.W.-S., Schattenberg, J.M., Romero-Gomez, M., Sebastiani, G., Castera, L., Hassan, C., Manousou, P., Miele, L., Peck, R., *et al.*: Accuracy, reliability, and comprehensibility of chatgpt-generated medical responses for patients with nonalcoholic fatty liver disease. *Clinical Gastroenterology and Hepatology* **22**(4), 886–889 (2024)
- [16] Hristidis, V., Ruggiano, N., Brown, E.L., Ganta, S.R.R., Stewart, S.: ChatGPT vs Google for queries related to dementia and other cognitive decline: comparison of results. *Journal of Medical Internet Research* **25**, 48966 (2023)
- [17] Duong, D., Solomon, B.D.: Analysis of large-language model versus human performance for genetics questions. *European Journal of Human Genetics* **32**(4), 466–468 (2024)
- [18] Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F., Hamosh, A.: OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. *Nucleic acids research* **43**(D1), 789–798 (2015)
- [19] Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., *et al.*: The genotype-tissue expression (GTEx) project. *Nature genetics* **45**(6), 580–585 (2013)
- [20] OpenAI: Learning to Reason with LLMs. <https://openai.com/index/learning-to-reason-with-llms/> (2025)
- [21] Anthropic: Claude 3.5 Haiku (2024). <https://www.anthropic.com/claude/haiku>
- [22] AI, D.: DeepSeek-R1-Distill-Llama-8B (2025). <https://huggingface.co/deepseek-ai/DeepSeek-R1-Distill-Llama-8B>
- [23] Team, G., Georgiev, P., Lei, V.I., Burnell, R., Bai, L., Gulati, A., Tanzer, G., Vincent, D., Pan, Z., Wang, S., *et al.*: Gemini 1.5: Unlocking multimodal understanding across millions of tokens of context. *arXiv preprint arXiv:2403.05530* (2024)
- [24] AI, M.: Meta Llama 3.1: Advancing Open-Source AI Models (2024). <https://ai.meta.com/blog/meta-llama-3-1/>

- [25] Team, Q.: Qwen2.5: A Party of Foundation Models (2024). <https://qwenlm.github.io/blog/qwen2.5/>
- [26] xAI: Grok 3: Next-Generation Intelligence from xAI (2025). <https://x.ai/blog/grok-3>
- [27] Lewis, P., Perez, E., Piktus, A., Petroni, F., Karpukhin, V., Goyal, N., Küttler, H., Lewis, M., Yih, W.-t., Rocktäschel, T., *et al.*: Retrieval-augmented generation for knowledge-intensive nlp tasks. *Advances in neural information processing systems* **33**, 9459–9474 (2020)
- [28] Wei, J., Wang, X., Schuurmans, D., Bosma, M., Xia, F., Chi, E., Le, Q.V., Zhou, D., *et al.*: Chain-of-thought prompting elicits reasoning in large language models. *Advances in neural information processing systems* **35**, 24824–24837 (2022)
- [29] Guo, D., Yang, D., Zhang, H., Song, J., Zhang, R., Xu, R., Zhu, Q., Ma, S., Wang, P., Bi, X., *et al.*: Deepseek-r1: Incentivizing reasoning capability in llms via reinforcement learning. *arXiv preprint arXiv:2501.12948* (2025)
- [30] Fang, J., Zhang, P., Zhou, Y., Chiang, C.-W., Tan, J., Hou, Y., Stauffer, S., Li, L., Pieper, A.A., Cummings, J., *et al.*: Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. *Nature Aging* **1**(12), 1175–1188 (2021)
- [31] Ongen, H., Buil, A., Brown, A.A., Dermitzakis, E.T., Delaneau, O.: Fast and efficient qtl mapper for thousands of molecular phenotypes. *Bioinformatics* **32**(10), 1479–1485 (2016)
- [32] Zhang, Y., Yang, H.T., Kadash-Edmondson, K., Pan, Y., Pan, Z., Davidson, B.L., Xing, Y.: Regional variation of splicing QTLs in human brain. *The American Journal of Human Genetics* **107**(2), 196–210 (2020)